BCR/ABL1
<p>Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia</p>
... JAK2, BCR/ABL1, ABL1 and EPOR revealed that of the 100 interphase cells analyzed, 36 (36%) showed ABL1 gene deletion but no rearrangement, and the rest showed no ...using ...
8
Application of tri-colour, dual fusion fluorescence in situ hybridization (FISH) system for the characterization of BCR-ABL1 fusion in chronic myelogenous leukaemia (CML) and residual disease monitoring
... with chronic myelogenous leukaemia in chronic phase in June 2006. He was commenced on 400 mg imatinib daily with complete haematological response and resolution of splenomegaly within 2 months. Interphase D-FISH on ...
6
Transposon-mediated generation of BCR-ABL1 -expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors
... SB- or by LV-mediated gene transfer. After selection of successfully transformed cells using a fluorescence protein marker and IL-3 depletion, cells were either sorted for low fluorescence, as displayed in Figure 2A and ...
12
Clinicopathological Variables and Outcome in Chronic Phase Chronic Myeloid Leukemia Associated with BCR-ABL1 Transcript Type and Body Weight
... analyses were done using statistical packages SPSS 22.0 (SPSS Inc. Chicago, IL) and Epi-info (Centers for Disease Control and Prevention, Atlanta, GA) software. Results: The study cohort included 26 males (70.3%) and 11 ...
10
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
... of BCR-ABL1 the increase in STAT5 expression leads to an increased probability to acquire a ROS mediated mutation rendering the BCR-ABL1 kinase less responsive to TKIs, a well- documented ...
19
A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case
... the BCR-ABL1 oncoprotein and inhibiting its cell signal transduction activity ...novel BCR-ABL1 fusion gene in our patient, imatinib was used at 400 mg/day as a targeted ...by ABL1 ...
5
Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia
... cases with purely episomal fusion genes, there was no evi- dence of the fusion genes on conventional cytogenetic analysis. Therefore, in the absence of specific FISH ana- lysis, these chromosomal fusions may never have ...
5
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients
... of BCR- ABL1 transcripts and to test whether this could reliably predict for emerging, clinically actionable ...NGS-based BCR-ABL1 mutation screening assay had already been demonstrated, as ...
9
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
... patients were monitored by NGS irrespective of their re- sponse to the ongoing TKI therapy [29–31, 34]. More- over, a recently completed prospective multicenter study (“NEXT-in-CML”) has shown that low-level, known ...
11
An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
... A 17-year-old girl was diagnosed with common ALL (cALL) in January 2013 after experiencing one month of fatigue, bone pain at rest, and lymphocytosis in the periph- eral blood (lymphocytes 86%). A complete blood count ...
6
FISH mapping of Philadelphia negative BCR/ABL1 positive CML
... The fusion gene was located at 9q34.1 in 3 patients, at 22q11.2 in 5 patients and CML-T1, and at 22p11 in another patient. 5 out of the 6 cases with a 9q34 insertion at 22q11 displayed recurrent distal breakpoints that ...
13
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
... 19 BCR-ABL1 positive cell lines were resistant to imatinib-induced apoptosis (KCL-22, MHH-TALL1, NALM-1, SD-1, ...of BCR-ABL1 and all showed resistance to second generation TKI, nilotinib or ...
10
A novel <em>BCR-ABL1</em> mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
... of BCR-ABL1 have been described to impair protein ...of BCR- ABL1, patients harboring this mutation typically do not respond to this TKI or other first-line TKIs, but are more sensitive to ...
10
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
... of BCR-ABL1 fusion transcript ...p210 BCR-ABL1 may be encoded by a number of different ...the BCR gene around exon 13 fused to exon 2 of the ABL1 ...the BCR gene around ...
9
BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
... The identification of prognostic molecular markers may be important to characterize the response of CML patients subjected to current treatments. The aim of this study was to detect the different transcript types of p210 ...
5
Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
... In our study, we used FISH with a range of BAC probes from 9q34.1-qter on a collection of chromosome suspen- sions from CML patients and human CML cell lines in order to investigate whether the bone marrow cells with an ...
12
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
... of BCR-ABL1 kinase ...for BCR-ABL ...the BCR-ABL active FDCB-Mix ...targeting BCR-ABL kinase activity by ima- tinib or siRNA significantly inhibits the BCR-ABL while increasing ...
10
A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia
... the BCR gene fragment at the 5′ end and the ABL1 gene fragment at the 3′end ...in-frame BCR-ABL1 fusion gene is likely oncogenic, which can be transcribed into BCR-ABL1 fusion ...
7
Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia
... leukemia stem and progenitor cells (LSC/LPC) from CP CML patients were found to have higher (2- to 4-fold) ROS levels compared to normal HSC, which were not corrected by inhibition of BCR-ABL1 kinase ...
14
Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH
... of BCR-ABL1 T315I mutation In addition, for the detection of T315I mutation in pro- genitor cells we set up a method based on fluorescently- labelled PNA probe (PNA ...human BCR-ABL1 T315I ...
5